SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

Multiple acquisition offers for ZIM Integrated Shipping Services, including bids from major international shipping firms, are currently sparking intense community discussion after the board rejected the CEO's internal proposal as significantly undervalued. Investors are keenly watching for a potential bidding war, emphasizing the company's substantial cash holdings and intrinsic worth, while also considering the Israeli government's critical role in approving any sale due to national security and worker concerns.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Significant token burns and a planned future supply reduction are fueling conversation around Venice Token, as its growing platform utility and new partnerships position it as a potentially undervalued private AI play. Community members are actively discussing its low market cap and strong fundamentals in the high-growth AI sector.

Credit Acceptance Corp. engages in the provision of dealer financing programs that enables automobile dealers to sell vehicles to consumers, regardless of its credit history. Its financing programs are offered through a nationwide network of automobile dealers who benefit from sales of vehicles to consumers. The company was founded by Donald A. Foss in 1972 and is headquartered in Southfield, MI.

Credit Acceptance Corp.

Recent strong earnings have propelled Credit Acceptance, defying broader macro trends and a challenging credit environment. However, the community actively debates the long-term viability of its subprime auto lending model amid concerns about rising delinquencies and falling used car values, highlighting significant short interest.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is seeing intense debate as recent weak earnings and the costly divestiture of Del Taco amplify concerns over its considerable debt and operational turnaround, while a prominent activist investor's growing stake and high short interest spark hopes for a potential short squeeze.

Meritage Homes Corp. engages in the design and construction of single-family attached and detached homes. It operates through the Homebuilding and Financial Services segments. The Homebuilding segment acquires and develops lands, constructs homes, markets and sells those homes, and provides warranty and customer services. The Financial Services segment offers title and escrows, mortgage, and insurance services. The company was founded by Steven J. Hilton and William W. Cleverly in 1985 and is headquartered in Scottsdale, AZ.

Meritage Homes Corp.

Meritage Homes is attracting investor attention following a series of quarterly financial results that have consistently exceeded expectations and recent analyst upgrades. The community is actively debating the potential for a housing market rebound driven by anticipated rate shifts, though concerns about sticky mortgage rates and affordability remain prevalent across the broader homebuilding sector.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq is trending after reporting strong Q4 earnings and a significant insider buy, with community discussion focused on its strategic moves toward 23-hour trading and tokenized securities as key steps to evolve market structure and unlock future growth.

Tortoise Energy Infrastructure Corp. operates as a mutual fund closed-end investment trust. The company owns a portfolio of master limited partnership investments in the energy infrastructure sector. Its objective is to provide its stockholders a high level of total return with an emphasis on current distributions. The company was founded on October 29, 2003 and is headquartered in Leawood, KS.

Tortoise Energy Infrastructure Corp

Tortoise Energy Infrastructure Corp.

TYG is trending as investors eye its increased monthly distribution following a recent merger, with community sentiment divided between those anticipating further drops and others aggressively accumulating shares in this high-yield energy infrastructure fund.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is trending following its recent partnership with AT&T to expand decentralized Wi-Fi, fueling both renewed bullish optimism and ongoing community debate regarding the token's long-term value and mining profitability, especially with upcoming tokenomic changes.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics Inc.

Palvella Therapeutics Inc

Palvella Therapeutics is trending following impressive positive topline Phase 2 data for its QTORIN rapamycin in cutaneous venous malformations, fueling a wave of analyst upgrades and significantly raised price targets. The community is highly optimistic about the drug's broad potential across multiple rare skin conditions, solidifying its "pipeline-in-a-product" narrative.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the following segments: FPL and NEER. The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEra Energy is trending as its partnerships with tech giants to power data centers, including a significant nuclear plant restart, underscore its critical role in meeting surging AI-driven electricity demand. The community is actively debating NEE's long-term growth potential amidst mixed earnings reports and evolving energy policy landscapes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Surge In Jaguar Health Stock: What's Happening Now?

Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty.read more...

June 26, 2025<a target="_blank" rel="noopener noreferrer nofollow" href="https://jaguarhealth.gcs-web.com/node/15251/pdf">PDF Version</a>Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of valueSAN FRANCISCO, CA / <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 26, 2025 / <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue6">Jaguar Health, Inc.</a> (<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue7">NASDAQ:JAGX</a>) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset."Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company."Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue8">Canalevia</a>® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue9">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buea">https://jaguar.health</a>Napo Pharmaceuticals, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueb">www.napopharma.com</a>Napo Therapeutics, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buec">napotherapeutics.com</a>Magdalena Biosciences, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bued">magdalenabiosciences.com</a>Canalevia-CA1, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buee">canalevia.com</a>Visit the Make Cancer Less Shitty patient advocacy program on <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buef">Bluesky</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueg">X</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueh">Facebook</a> &amp; <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buei">Instagram</a>Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.CONTACT: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a> Jaguar-JAGXSOURCE:&nbsp;Jaguar Health, Inc. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-board-of-directors-authorizes-company-to-include-crypto-1043232">press release</a>

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Others

Investor retail chatter spiked for Jaguar Health Inc. on Wednesday after the company revealed its plan for a $1.5 million registered direct offering priced at-the-market under Nasdaq rules.Jaguar Health shares fell 27.05% to close at $4.26 on Wednesday, before recovering 3.99% in after-hours trading to $4.43.The biopharmaceutical company finalized agreements to exchange 246,306 shares of common stock for $6.09 per share.&nbsp;Jaguar will distribute unregistered warrants in a simultaneous private placement. The exercise price is $5.84 per share, and purchasers can buy up to 492,612 shares.&nbsp;These warrants become exercisable immediately and expire after a fundamental transaction or liquidation event occurs or after 24 months, whichever condition is first met.The offering's closure is scheduled for May 22, subject to standard conditions. H.C. Wainwright &amp; Co. holds exclusive placement agency responsibilities.Jaguar plans to use net proceeds to finance general corporate purposes, such as growth capital funding, working capital maintenance, convertible note repayment, and capital expenditure needs.On Stocktwits, retail sentiment was ‘bullish’ amid a 444% surge in 24-hour message volume.Some retail traders described the offering as a “dip opportunity,” pointing to prior disclosures about share sales through the at-the-market program and suggesting the move had been anticipated since 2022.&nbsp;<stembedurl>https://stocktwits.com/jimiinfinity/message/615411703</stembedurl>Others framed the discounted pricing as a potential entry point, expressing optimism about upcoming news and the company’s trajectory.<stembedurl>https://stocktwits.com/Torobravo_1/message/615384587</stembedurl>The stock has declined 84.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’

Jaguar Health is raising $1.5 million through a registered direct offering and concurrent private warrants placement to support general corporate and growth initiatives.

Equity

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

This account has been verified as an official JAGX representative.

Verified Account

Jagaur Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

JAGX
Jaguar Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAGX News

JAGXJaguar Health Inc